Reported purityBlend Verified
Task number#150932
Tested22 APR 2026
VerificationReport available
About CJC-1295 no DAC + Ipamorelin
Independently quantified peptide blend
Sulan Bio CJC-1295 no DAC + Ipamorelin batch SUL0330-001 was independently analysed by Janoshik Laboratory under task #150932.
The analytical report recorded 5.24mg CJC-1295 no DAC (MOD GRF 1-29) and 5.21mg Ipamorelin in the submitted sample, providing component-specific quantitative documentation for this marketplace listing.
The two measured components provide a combined measured peptide content of 10.45mg compared with the nominal 5mg + 5mg configuration.
What is CJC-1295 no DAC + Ipamorelin?
This research blend combines CJC-1295 no DAC (MOD GRF 1-29) with Ipamorelin. The two peptides are of research interest because they interact with different receptor systems involved in growth hormone secretory signalling.
CJC-1295 no DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue studied for its interaction with the GHRH receptor and its relationship with pulsatile growth hormone signalling.
Ipamorelin is a growth hormone secretagogue studied primarily for its activity at the growth hormone secretagogue receptor (GHSR), also known as the ghrelin receptor.
Common research areas
CJC-1295 no DAC and Ipamorelin are commonly investigated in laboratory and endocrine research examining:
- GHRH receptor signalling
- GHSR / ghrelin receptor signalling
- Growth hormone release and regulation
- Pulsatile growth hormone secretory pathways
- Pituitary signalling mechanisms
- GH/IGF-1 axis activity
- Endocrine signalling and regulation
- Interactions between distinct growth hormone secretagogue pathways
Two distinct signalling pathways
A key area of research interest in this blend is that its two components interact with different receptor systems. CJC-1295 no DAC is associated with GHRH receptor signalling, while Ipamorelin is associated with GHSR / ghrelin receptor signalling.
This makes the combination relevant to experimental models examining how separate upstream signalling pathways interact in the regulation of pituitary growth hormone release and downstream GH/IGF-1 signalling.
About CJC-1295 no DAC
CJC-1295 no DAC, commonly referred to as MOD GRF 1-29, does not contain the Drug Affinity Complex associated with longer-acting CJC-1295 variants.
Its comparatively short-lived signalling profile makes it of particular interest in laboratory research examining pulsatile GHRH receptor activation and growth hormone secretory mechanisms.
Available configuration
- CJC-1295 no DAC: nominal 5mg per vial
- Ipamorelin: nominal 5mg per vial
- Total nominal peptide content: 10mg per vial
- Box configuration: 10 vials
- MOQ: 10 vials / 1 box
- Format: Lyophilized research peptide blend
- Supplier: Sulan Bio
Batch verification
- Supplier: Sulan Bio
- Batch: SUL0330-001
- Nominal blend: 5mg CJC-1295 no DAC + 5mg Ipamorelin
- Measured CJC-1295 no DAC: 5.24mg
- Measured Ipamorelin: 5.21mg
- Measured combined content: 10.45mg
- Independent laboratory: Janoshik
- Task number: #150932
- Tested: 22 APR 2026
- COA status: Quantitative analysis available
This product is supplied strictly for laboratory research and analytical applications. It is not intended for human consumption, medical use, diagnostic use or clinical application.
PurityBlend Verified
Format10MG
MOQ10 vials / 1 box
Ships fromChina
Laboratory report
This listing is provided for laboratory and research sourcing review. It is not intended for human consumption, medical use or self-administration.